Gemcitabine is an effective agent in pancreatic adenocarcinoma. Fixed-dose-rate gemcitabine has an interesting biological and clinical rationale, with successful results in previous studies. We conducted a trial to confirm efficacy and toxicity of fixed-dose-rate gemcitabine in patients with pancreatic or biliary tree adenocarcinoma.
Methods
Eligible patients with locally advanced or metastatic pancreatic or biliary tree adenocarcinoma received fixed-dose-rate gemcitabine at a dose of 1500 mg/m2 at a rate of 10 mg/m2/min weekly for 3 weeks every 28 days. Efficacy measures were overall survival, response rate and progression-free survival.
Results
Sixty-two patients were enrolled, and 59 were assessable for response. Seven patients (11.3%) had a partial response, 26 stable disease (41.9%) and 26 progressive disease (41.9%). Median time to progression was 21 weeks and median overall survival, 37.71 weeks. Main toxicities were grade 3–4 neutropenia (45.2%) and grade 2–3 asthenia (54.8%). No toxic deaths were documented.
Conclusions
Fixed-dose-rate gemcitabine has a relevant antitumor activity but with significant toxicity. It represents an interesting schedule and could be combined with other biological or chemotherapeutic agents.
JemalA., SiegelR., WardE., HaoY., XuJ., MurrayT., ThunM.J.: Cancer statistics, 2008. CA Cancer J Clin, 58: 71–96, 2008.
2.
NakeebA., PittH.A., SohnT.A., ColemanJ., AbramsR.A., PiantadosiS., HrubanR.H., LillemoeK.D., YeoC.J., CameronJ.L.: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg, 224: 463–473, 1996.
3.
BurrisHAIII, MooreM.J., AndersenJ., GreenM.R., RothenbergM.L., ModianoM.R., CrippsM.C., PortenoyR.K., StornioloA.M., TarassoffP., NelsonR., DorrF.A., StephensC.D., Von HoffD.D.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15: 2403–2413, 1997.
4.
PenzM., KornekG.V., RadererM., Ulrich-PurH., FiebigerW., ScheithauerW.: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol, 12: 183–186, 2001.
5.
DingleB.H., RumbleR.B., BrouwersM.C.: Cancer Care Ontario's Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol, 19: 711–716, 2005.
6.
GrunewaldR., KantarjianH., KeatingM.J., AbbruzzeseJ., TarassoffP., PlunkettW.: Pharmacologically directed design of the dose rate and schedule of 2′, 2′-difluorodeoxycytidine (gemcitabine) administration in leukaemia. Cancer Res, 50: 6823–6826, 1990.
7.
AbbruzzeseJ.L., GrunewaldR., WeeksE.A., GravelD., AdamsT., NowakB., MineishiS., TarassoffP., SatterleeW., RaberM.N.: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol, 9: 491–498, 1991.
8.
TemperoM., PlunkettW., Ruiz Van HaperenV., HainsworthJ., HochsterH., LenziR., AbbruzzeseJ.: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol, 21: 3402–3408, 2003.
9.
GelibterA., MalagutiP., Di CosimoS., BriaE., RuggeriE.M., CarliniP., CarboniF., EttorreG.M., PellicciottaM., GiannarelliD., TerzoliE., CognettiF., MilellaM.: Fixed dose-rate gemcitabine infusión as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer, 104: 1237–1245, 2005.
10.
PoplinE., FengY., BerlinJ., RothenbergM.L., HochsterH., MitchellE., AlbertsS., O'DwyerP., HallerD., CatalanoP., CellaD., BensonAB3rd: Phase III, randomozed study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma. E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 27: 3778–3785, 2009.
11.
LouvetC., LabiancaR., HammelP., LledoG., ZampinoM.G., AndreT., ZaniboniA., DucreuxM., AitiniE., TaïebJ., FarouxR., LepereC., de GramontA.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol, 23: 3509–3516, 2005.
12.
HeinemannV., LabiancaR., HinkeA., LouvetC.: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol, 18: 1652–1659, 2007.
13.
MooreM.J., GoldsteinD., HammJ., FigerA., HechtJ.R., GallingerS., AuH.J., MurawaP., WaldeD., WolffR.A., CamposD., LimR., DingK., ClarkG., Voskoglou-NomikosT., PtasynskiM., ParulekarW.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25: 1960–1966, 2007.
14.
KaplanE.L., MeierP.: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457–481, 1958.
15.
KanatO., EvrenselT., KurtE., DemirayM., GonulluG., ArslanM., ManavogluO.: Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study. Tumori, 90: 192–195. 2004.
16.
SultanaA., SmithC.T., CunninghamD., StarlingN., NeoptolemosJ.P., GhanehP.: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol, 25: 2607–2615, 2007.
17.
KindlerH.L., NiedzwieckiD., HollisD.: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol, 25: 199s, 2007.
18.
Van CutsemE., VervenneW.L., BennounaJ., HumbletY., GillS., Van LaethemJ.L., VerslypeC., ScheithauerW., ShangA., CosaertJ., MooreM.J.: Phase III Trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol, 27: 2231–2237, 2009.
19.
CarneiroB.A., BrandR.E., FineE., KnopR.H., KhandekarJ.D., UhliqW., LockerG.Y.: Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma. Cancer Invest, 25: 366–371, 2007.
20.
OkusakaT., IshiiH., FunakoshiA., YamaoK., OhkawaS., SaitoS., SaitoH., TsuyuguchiT.: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol, 57: 647–53, 2006.
21.
EngC., RamanathanR.K., WongM.K., RemickS.C., DaiL., Wade-OliverK.T., ManiS., KindlerH.L.: A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol, 27: 565–569, 2004.
22.
BernhardJ., DietrichD., ScheitauerW., GerberD., BodokyG., RuhstallerT., GlimeliusB., BajettaE., SchüllerJ., SalettiP., BauerJ., FigerA., PestalozziB.C., KöhneC.H., MingroneW., StemmerS.M., TàmasK., KornekG.V., KoeberleD., HerrmannR.: Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus capecitabine alone: A randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol, 26: 3695–3701, 2008.
23.
GridelliC., GalloC., CeribelliA., GebbiaV., GamucciT., CiardielloF., CarozzaF., FavarettoA., DanieleB., GalettaD., BarberaS., RosettiF., RossiA., MaioneP., CognettiF., TestaA., Di MaioM., MorabitoA., PerroneF.: Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. Lancet Oncol, 8: 500–512, 2007.
